Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD+ aml Patients

Koneru, Mythili; Arslan, Shukaib; Magalhaes-Silverman, Margarida; Liu, Hongtao; Bejanyan, Nelli; Stasi, Antonio Di; McCallum, R. B.; Quintero, Silvia; Garrett, Gerald R.; Wang, Karrie; Smith, Eric E.; Shahim, Tara; Hoang, Lina; Crisostomo, Jeannette; Wilga-Savitski, Anna; Pickering, Jennifer; Angelo, Laura; Smith, Anastasiya; Vera, Juan F.; Oran, Betül; Hsu, Jingmei

doi:10.1182/blood-2022-155602

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with negative MRD pre-transplant or positive MRD post-transplant had better relapse-free survival under sorafenib compared to patients with undetectable MRD pre-transplant or detectable MRD post-transplant under placebo. The ARTEMIS trial [74], evaluating the effectiveness of Zedenoleucel (MT-401), an allogeneic multi-tumor-associated antigen-specific T cell therapy, also showed promising results in terms of efficacy and tolerance by converting postallograft positive MRD to negative. (4) As a surrogate endpoint in clinical trials, using the terms "AML" and "MRD" on the ClinicalTrials.gov website, approximately 324 clinical trials have been conducted, with 143 currently recruiting patients.…”

Section: Clinical Trials and Clinical Rolementioning

confidence: 99%

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

Chea,

Rigolot,

Canali

et al. 2024

IJMS

View full text Add to dashboard Cite

Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.

show abstract

Section: Clinical Trials and Clinical Rolementioning

confidence: 99%